Organon & Co. (OGN)

Organon & Co.'s stock price has experienced a significant decline over the past year. In October 2025, the company's stock price plummeted following the announcement of an Audit Committee investigation into improper wholesale sales practices for its Nexplanon product and the resignation of CEO Kevin Ali. In November 2025, Organon announced the US FDA approval of POHERDY and an agreement to divest its Jada® System. Organon shifted its focus to accelerate debt reduction, which included slashing the quarterly dividend from $0.28 to $0.02 per share.

Organon's product portfolio indicates some demand seasonality, particularly within its Established Brands segment. Respiratory products can experience increased demand associated with seasonally poor air quality in certain regions.

Organon & Co. is a global healthcare company focused on developing and delivering health solutions through prescription therapies and medical devices, operating within the Pharmaceuticals sector. Its business model is structured around three franchises: Women's Health, Biosimilars, and Established Brands. Major products include contraception and fertility brands, biosimilars spanning immunology and oncology, and a portfolio of mature medicines across various therapeutic areas.

Organon & Co. has a significant global presence, with products available in over 140 countries, and approximately 75% of sales generated outside the United States. The company's operations span regions including the United States, Europe, Canada, Japan, the rest of Asia Pacific, Latin America, the Middle East, Russia, and Africa. Organon also operates manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the UK.

Organon's brand reputation was significantly impacted in October 2025 by the revelation of an internal investigation into improper wholesale sales practices for its Nexplanon product. Despite this negative event, Organon has received positive recognition, including being recognized as a "Best Place to Work for Disability Inclusion" and included in "America's Most JUST Companies, JUST 100 Index" in 2025. In 2023, it was recognized by Fortune for "Change the World" and awarded "Organization of the Year with the Power to Generate Change Towards Gender Equity".

Organon & Co. is predominantly controlled by institutional investors, who held over 82% of the company's shares as of late 2025. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., Massachusetts Financial Services Co., State Street Corp., iShares Core S&P Small-Cap ETF (IJR), LSV Asset Management, Geode Capital Management, Llc, and Millennium Management Llc. Individual investor ownership is calculated as the remainder of the float, and insider ownership remains minimal, although Executive Chair Carrie Cox bought US$502k in stock in November 2025.